The identified hub genes—MYC, EGFR, CDKN2A, ERBB2, CDK1, E2F1, TOP2A, MDM2, TGFB1, and FOXM1—play significant roles in BC progression and are potential biomarkers for diagnosis, prognosis, and therapy. This evidence concerns the gene MDM2 and breast cancer.